Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level

We describe here a case of nivolumab-induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment. Anti-programmed cell death protein 1 (PD-1) antibodies activate the immune system to attack tumors and are used as anticancer agents. However, anti-PD-1 antibody therapy is reported to induce serious side-effects, including type 1...